Cancer Vaccine


Also found in: Wikipedia.
A vaccine that either prevents infections with cancer-causing viruses—e.g., HPV—treats existing cancer or prevents the development of cancer in certain high risk individuals. The first effective cancer vaccine is that for preventing cervical cancer. Dendreon Corp’s Provenge, a vaccine for advanced prostate cancer, was approved by the FDA in 2010 and adds about 4 months of life to the average person’s lifespan, at an estimated cost of $100,000. Other CV candidates include peptides, proteins, whole cancer cells, dendritic cells, gangliosides, heat-shock proteins, viral and bacterial vectors, and oligonucleotides
References in periodicals archive ?
They were there in our house to inquire if we have knowledge when their teen girls will be given their second dose of the anti-cervical cancer vaccine.
for its lead product candidate eftilagimod alpha as part of a cancer vaccine. The agreements enable the two parties to collaborate on clinical trials to evaluate efti as part of a therapeutic cancer vaccine containing CYTLIMIC's innovative cancer peptide vaccine, called CYT001.
The companies will collaborate on clinical trials to evaluate efti as part of a therapeutic cancer vaccine containing CYTLIMIC's cancer peptide vaccine, called CYT001.
Dubai: A top official on Tuesday denied media reports that cervical cancer vaccine will be made mandatory for schoolgirls in Dubai and Northern Emirates.
Moderna Therapeutics and Merck, known as MSD outside the United States and Canada, have expanded their 2016 collaboration to develop and commercialize novel personalized messenger RNA (mRNA) cancer vaccines to now include shared antigen mRNA cancer vaccines including mRNA- 5671, Moderna's mRNA KRAS cancer vaccine.
M2 EQUITYBITES-May 31, 2018-BlueWillow Biologics wins therapeutic cancer vaccine patent in the US
"Pending replication in humans, our findings indicate these cells may one day serve as a true patient-specific cancer vaccine."
As a result, neoantigens appear to represent the ideal targets for therapeutic cancer vaccine and T cell-based cancer immunotherapy.
Dr Knut Elbers, Boehringer Ingelheim Venture Fund representative on AMAL's Board added: "We believe that AMAL's KISIMA technology could revolutionise the peptide-based cancer vaccine field - bringing an innovative new technology to the patient, this is why we invested as seed investor in the company.
Johnathan's presentation will be focused on the 'Enhanced Cancer Vaccine Effectiveness With NKTR-214 A CD 122-Biased Cytokine'.
As of now, the cancer vaccine takes months to make and is very costly.
A new Cuban lung cancer vaccine is coming to the United States, the Roswell Park Cancer Center (https://www.roswellpark.org/media/news/gov-cuomo-announces-landmark-roswell-park-study-bringing-cuban-lung-cancer-vaccine-us) announced Wednesday.

Full browser ?